Список литературы

1. Hirschhorn R., Reuser A. Glycogen storage disease Type II: acid alpha-glucosidase (acid maltase) deficiency//In: Scriver C, Beaudet A, Sly W, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York. 2001. P. 3389 - 3420.

2. http://www.hgmd.cf.ac.uk

3. Hagemans M., Winkel, Hop W. et al. Disease severity in children and adults with Pompe disease related to age and disease duration//Neurology. 2005. V. 64. P. 2139 - 41.

4. Muller-Felber W., Horvath R., Gempel K. et al. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients//Neuromuscul Disord. 2007. V. 17. P. 698 - 706.

5. Wokke J.H., Escolar D.M., Pestronk A. et al. Clinical features of late-onset Pompe disease: a prospective cohort study//Muscle Nerve. 2008. V. 38. N 4. P. 1236 - 45.

6. Barba-Romero M.A., Barrot E., Bautista-Lorite J. et al. Clinical guidelines for late-onset Pompe disease//Rev Neurol. 2012. V. 54. N 8. P. 497 - 507.

7. Meikle P.J., Hopwood J.J., Clague A.E., Carey W.F. Prevalence of lysosomal storage disorders//JAMA. 1999. V. 281. N 3. P. 249 - 54.

8. Ausems M.G., Verbiest J., Hermans M.P. et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counseling//Eur J Hum Genet. 1999. V. 7. N 6. P. 713 - 6.

9. Mechtler T.P., Stary S. et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria//Lancet. 2012. V. 379. N 9813. P. 335 - 41.

10. Chiang S.C., Hwu W.L., Lee N.C., Hsu L.W., Chien Y.H. Algorithm for Pompe disease newborn screening: results from the Taiwan screening program//Mol Genet Metab. 2012. V. 106. P. 281 - 6.

11. Zhao Y., Wang Z., Lu J. et al. Characteristics of Pompe disease in China: a report from the Pompe registry//Orphanet J Rare Dis. 2019. V. 14. N 78. doi: 10.1186/s13023-019-1054-60.

12. van den Hout H.M. P., Hop W. et al. The Natural Course of Infantile Pompe's Disease: 20 Original Cases Compared With 133 Cases//Literature Pediatrics. 2003. V. 112. N 2. 332 - 40.

13. Chien Y., Lee N., Thurberg B. et al. Pompe disease in infants: Improving the prognosis by newborn screening and early treatment//Pediatrics. 2009. V. 124. P. e1116 - e1125.

14. Котлукова Н.П., Михайлова С.В. и др. Младенческая форма болезни Помпе: клиника, диагностика и лечение//Нервно-мышечные болезни. 2012. N 4. С. 66 - 74.

15. Kishnani P., Steiner R.D., Bali D. et al. Pompe disease diagnosis and management guideline//Genetics in Medicine. 2006. V. 8. N 5. P. 267 - 88.

16. Van Der Beek N.A., De Vries J.M., Hagemans M.L. et al. Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study//Orphanet J Rare Dis. 2012. V. 7. P. 88.

17. Cupler E.J., Berger K.I., Leshner R.T. et al. Consensus treatment recommendations for late onsent Pompe disease//Muscle Nerve. 2012. V. 45. N 3. P. 319 - 33.

18. Клюшников С.А., Загоровская Т.Б. и др. Клинический случай болезни Помпе с поздним началом//Нервные болезни. 2015. N 2. С. 38 - 43.

19. Курбатов С.А., Никитин С.С., Захарова Е.Ю. Болезнь Помпе с поздним началом с фенотипом поясно-конечностной миодистрофии//Нервно-мышечные болезни. 2015. N 3. С. 65 - 68.

20. Никитин С.С., Ковальчук М.О. и др. Болезнь Помпе с поздним началом: первое клиническое описание в России//Нервно-мышечные болезни. 2014. N 1. С. 62 - 8.

21. Никитин С.С. Бессимптомная гиперкреатинкиназемия в клинике нервно-мышечных болезней//Неврологический журнал. 2015. Т. 20. N 5. С. 26 - 33.

22. Никитин С.С., Курбатов С.А., Бределев В.А., Ковальчук М.О. Настораживающие признаки и симптомы в ранней диагностике болезни Помпе с поздним началом: клиника превыше всего//Журнал неврологии и психиатрии им. С.С. Корсакова. 2015. N 12. С. 19 - 24.

23. Desnuelle C. Поздняя форма болезни Помпе: диагностические и терапевтические подходы//Нервно-мышечные болезни. 2012. N 3. С. 20 - 33.

24. Methods for a prompt and reliable laboratory diagnosis of Pompe disease: Report from an international consensus meeting Molecular Genetics and Metabolism 93 (2008) 275 - 281.

25. Panagopoulou V., Deftereos S., Kossyvakis C. NTproBNP: an important biomarker in cardiac diseases//Curr Top Med Chem. 2013. V. 13. N 2. P. 82 - 94.

26. Ермоленко В.С., Сильнова И.В., Басаргина Е.Н. Динамика содержания в крови n-концевого фрагмента мозгового натрийуретического пептида (NT-proBNP) при гипертрофической кардиомиопатии у детей//Российский педиатрический журнал. 2016. Т. 19. N. 2.

27. Bembi B., Cerini E., Danesino C. et al. Management and treatment of glycogenosis type II//Neurology. 2008. V. 71. P. 12 - 36.

28. Schoser B., Stewart A., Kanters S. et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis//J Neurol. 2017. V. 264. P. 621 - 30.

29. Toscano A., Schoser B. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review//J Neurol. 2013. V. 260. N 4. P. 951 - 9.

30. Kishnani P., Corzo D., Leslie N. et al. Early treatment with alglucosidase alfa prolongs long term survival of infants with Pompe disease//Pediatr Res. 2009. V. 66. N 3. P. 329 - 35.

31. Llerena J.C., Horovitz D.M., Nagahashi Marie S.K. et al. The Brazilian Consensus on the Management of Pompe Disease//The Journal of pediatrics. V. 155. N 4. Suppl. 2. P. 47 - 56.

32. Byrne B.J., Kishnani P.S., Case L.E. et al. Pompe disease: Design, methodology, and early findings from the Pompe Registry//Molecular Genetics and Metabolism. 2011. V. 103. P. 1 - 11.

33. Taglia A., Picillo E., D"Ambrosio P., Cecio M.R., Viggiano E., Politano L. Genetic counseling in Pompe disease//Acta Myol. 2011. V. 30. N 3. P. 179 - 81.

34. Skirton H., Cordier C., Ingvoldstad C., Taris N., Benjamin C. The role of the genetic counsellor: a systematic review of research evidence//Eur J Hum Genet. 2015. V. 23. N 4. P. 452 - 8.

35. D, Kruijshaar ME, Plug I, et al. Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up. J Inherit Metab Dis. 2016; 39(2): 253 - 260.